key: cord-1025420-mpb5gwdj authors: Fang, Ling; Zhan, Yi; Qu, Liping; Sheng, Huafang title: The clinical efficacy and safety research of Lianhuaqingwen (LHQW) in treatment of COVID-19: A systematic review and meta-analysis date: 2022-04-02 journal: Pharmacological Research - Modern Chinese Medicine DOI: 10.1016/j.prmcm.2022.100092 sha: 5a1e2812b2e1db7393665ea10d86254b443c84ab doc_id: 1025420 cord_uid: mpb5gwdj Background : Although vaccines have been launched, COVID-19 has not been effectively curbed, and the number of infections is increasing. Compared with western medicine, Traditional Chinese Medicine has made some achievements in the treatment of COVID-19, which should be paid attention to and play a greater role. As a classical Chinese medicine prescription for treating pestilence, Lianhuaqingwen (LHQW) has gone to many countries with the Chinese medical team to participate in the local fight against the epidemic, which has been widely recognized. Methods : We searched MEDLINE, EMBASE, AMED, Chchrane Central Register of Controlled Trials (CENTRAL), PubMed, Web of Science, Chinese National Knowledge Infrastructure (CNKI), VIP Information Database (VIP), Chinese Biomedical Literature Database (CBM), and Wanfang Database from inception up to November 24, 2021, which formed the basis for evidence used to formulate recommendations. Sixteen randomized controlled trials (RCTs) involving 1896 patients were enrolled. LHQW is a traditional Chinese medicine compound preparation, which contains 13 traditional Chinese medicine (TCM) components. Two dosage formulations of LHQW were included: granule and capsule. The most commonly used dosage formulation was granule (15/17, 88.24 %), followed by capsule (2/17, 11.76 %). Conclusion : This systematic review and Meta analysis suggested that, in the treatment of COVID-19, LHQW Capsule (Granule) could not only significantly improve the fever symptoms, shorten the fever time, but also reduce the cough and fatigue symptoms, improve the clinical efficiency, improve the lung CT, significantly reduce the number of patients with mild to severe diseases, and have certain anti-inflammatory effect. And there is no server adverse events which support the safety of LHQW Capsule (Granule) for the treatment of COVID-19. As a classic formula of TCM, LHQW Capsule (Granule) could be used as potential candidates for COVID-19 in this battle. Currently, the cumulative number of confirmed cases on COVID-19 globally has been more than 250 million, and the cumulative number of deaths has reached 5.1 million. As a global pandemic, the epidemic continues to rage and shows no sign of stopping. Although vaccines have been launched, COVID-19 has not been effectively curbed, and the number of infections is increasing. As a responsible pow, China has taken strict epidemic prevention measures from the beginning, actively responded to the epidemic situation and achieved good results, in which Traditional Chinese Medicine (TCM) has also played an important role. Many scholars have studied the treatment of COVID-19 with TCM, with certain experimental data records and comparative analysis [1] [2] [3] [4] . For example, M.K. Yu et al. summed up a number of TCM clinical experts' prevention and treatment programs for providing advice, and found that the location of COVID-19 was mainly in the lung, and the etiology and pathogenesis were mostly the Qi of pestilence, mainly "dampness" [5] . The pharmacological research on the intervention of relevant Chinese herbal medicine, traditional Chinese medicine prescription and traditional Chinese medicine preparation on covid-19 inflammatory storm was summarized [6] . Compared with western medicine, Traditional Chinese Medicine has made some achievements in the treatment of COVID-19, which should be paid attention to and play a greater role. As a classical Chinese medicine prescription for treating pestilence, LHQW has gone to many countries with the Chinese medical team to participate in the local fight against the epidemic, which has been widely recognized. Although many articles have studied meta-analysis of LHQW in treatment of COVID-19, there are two obvious limitations. Firstly, the experimental results referred to in some articles were not comprehensive, which may be because the epidemic was still spreading in China at that time, and some new experimental results came out after the publication of the articles. Secondly, the analysis indicators in published results [7] [8] [9] [10] [11] [12] were not comprehensive. After the epidemic subsided in China, it is necessary to conduct a comprehensive combing and analysis. Literature [7] did not use randomized controlled experiments to study the effect of LHQW on COVID-19. Literature [8] focused on children, which should also be excluded. The control group studied in literature [9] was LHQW, and the experimental group was western medicine combined with LHQW. Literature [10] [11] [12] have a few experiments and a few indicators for comparison. Therefore, in this study, a systematic review of RCTs was performed to evaluate the current clinical efficacy and safety of LHQW in the treatment of COVID-19. At a time when the epidemic is still spreading around the world, such research is of great significance. It is not only an exchange of experience in treatment methods, but also an opportunity for the world to understand traditional Chinese medicine. The study was conducted in accordance with the guidelines for Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [13] and registered in the International Prospective Register of Systematic Reviews (PROSPERO, CRD42021292658). All RCTs trials that reported the clinical application of LHQW in the treatment of COVID-19 were included.There were no statistical differences in basic data such as size, age, sex ratio between the groups compared in the trials. Studies meeting the following conditions were excluded: (1) No distinction was made between the experimental group and the control group, or the experimental group did not include LHQW; (2) Duplicate studies reporting the same results; (3) The data was incomplete or cannot be extracted due to obvious errors; (4) No indicators of concern in the outcomes. All Patients with COVID-19 could be enrolled in this review. There were no restrictions on gender, age and nationality, to ensure the inclusion of all relevant studies. The dosage forms of LHQW prescription contain granule and capsule [14] [15] . Patients in the treatment group should be treated by LHQW Capsule or LHQW Granule and Conventional Western Medicine (CMW). Patients in the control group should be treated by CWM. CWM included symptomatic treatment, nutritional support treatment, antiviral and antibacterial drugs and other routine treatment. The name, dosage and dose of CWM in the treatment group and the control group must be the same. There are no restrictions on the dosage form, type, quantity or course of treatment of LHQW. The observation time ranged from 7 days to 14 days. The primary outcome measure was defined as lung CT, clinical cure rate, ranging from mild to critical cases, death, cough, fever, fatigue, length of hospital stay, time for nucleic acid conversion, total score of clinical symptoms; The second type was other clinical symptoms, including sore throat, chest tightness, anhelation, expectoration, muscle pain, sickness, headache, anorexia, diachoea; The third type was biological inflammation, including blood cell (WBC), Procalcitonin (PCT), lymphocyte (LYM), and C-reactive protein (CRP). The inclusion criteria comprised research papers related to case reports and case data, which reported the COVID-19 treatment with LHQW granules. Single arm research results were excluded because only some effects were verified without comparison, so its authority is unknown. In order to avoid repetition and wrong weight of research papers cited or discussed more frequently, review papers, meta-analysis, editorial letters and expert opinions are not included. The meeting minutes were also excluded because their complete research report could not be evaluated and their scientific rigor had not been peer reviewed. Considering that the research content belongs to the category of traditional Chinese medicine, studies published in Chinese language were included. All articles identified by searching seven databases are imported into Endnote for filtering. Screening included two rounds of studies. In the frist round, two researchers (Fang L and Sheng HF) independently evaluated all retrieved studies separately by reviewing titles, abstracts and key terms. In the second round of screening, full texts of the articles determined during the initial screening was retrieved and read in detail to assess their eligibility. Possible inconsistencies in the study selection process were discussed with a third reviewer (Zhan Y) to reach a consensus. Two independent researchers (Fang L and Sheng HF) collected information on study characteristics, treatment details, patient characteristics, and all patient-important outcomes as guided by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials. Basic data from the included studies, including the name of the first author, publication date, sample size, intervention and observation time of experimental group and control group, and outcome indicators. If any disagreement happens, a third researcher (Qu LP) will participate in the discussion and resolve it together. The methodological quality of the included trials was also independently assessed by two reviewers (Fang L and Zhan Y). According to the tools of Cochrane Collaboration, six fields of risk of bias (ROB) were evaluated as follows: random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (analysis bias), selective reporting (reporting bias), other bias. Each field was evaluated as "Yes"(low ROB), "No" (high rob), or "Unclear" (unclear ROB), and was given the same weight, and the overall bias of the trails was obtained. We utilized Revman 5.3 software to conduct the meta-analysis of dichotomous and continuous outcome measures extracted from original studies. Measurement data (continuous variables) were represented by standard mean variance (SMD) and 95% confidence interval (95% CI), while enumeration data (binary variables) were represented by relative risk (RR) and 95% CI. I 2 test was used for heterogeneity test. If P>0.1 and I 2 <50%, Fixed Effect model was selected , while P≤0.1 and I 2 ≥50%, heterogeneity between included studies was identified, Random Effect model was applied. Funnel plot was also used to assess publication bias. It was considered as marked difference when P<0.05. The initial search retrieved 2596 results from the above 7 electronic databases. All articles identified were imported into Endnote for screening. After removing duplicates, 1815 papers were remained. In the screening by reviewing titles, abstracts, and key terms related to LHQW and COVID-19, 1356 publications were excluded for less relevant, most of them were reviews, commentaries, editorials, case reports, case series, experimental researches, data mining articles. The rest 459 articles were identified to be potentially relevant and then assessed for eligibility. 405 articles were excluded as follows: 273 articles did conducted with LHQW, and 232 articles had no experimental data. After that, 38 articles were further excluded: participants did not meet the inclusion criteria (n = 21); duplicate publications (n = 2); no control group (n = 9); intervention included other medical therapies (n = 3); no clinical data for extraction (n = 3). Ultimately, 16 articles met all the inclusion criteria and were included in this review (Fig. 1 Basic features of the included studies and subjects were presented in Table 1 . Among the 16 included trials, 6 were multi-centered trials [16, 17, 18, 22, 24, 29] and the rest 10 were single-centered trials. All of the 16 studies were conducted in mainland China since 2020. 4 articles were online published in advance with English language [16, 22, 24, 28] , and the rest were in Chinese. There were altogether 1896 patients enrolled in this review, with the sample size ranged from 18 to 158. All the included trials evaluated the effects of LHQW combined with CWM treatment compared to CWM treatment alone. The name, usage, dosage of western medicine used in trial group should be the same as used in control group. There is no trial utilized LHQW placebo. Treatment duration varied from 6 to 15 days. All clinical outcomes were analyzed in detail in the following chapters. As shown in Table 2 , the methodological quality of the enrolled studies was evaluated based on the criteria in Cochrane handbook. Detailed information on sequence generation of randomization was reported in 6 trials (6/16, 37.5%) [16, 20, 23, 24, 25, 29] . Specific method of allocation concealment was not described in this review. 2 trials reported no application of blinding [24, 29] . 3 trials [16, 24, 29] were reported blinding of participants and personnel, and 2 trials [24, 29] were reported blinding of outcome assessment. We gave the same weight to the evaluation indicators and got an overall evaluation: 3 trails were medium risk and the other 13 were low risk. Blinding of participants and personnel (performance bias); D: Blinding of outcome assessment (detection bias); E: Incomplete outcome data (analysis bias); F: Selective reporting (reporting bias); G: Other bias; +: Low risk; -: High risk;? : Unclear. Ten trials assessed the efficacy of LHQW on lung CT [16, 17, 20, 21, 25, [27] [28] [29] [30] [31] . There were 608 patients in experimental group and 526 in control group. A significant improvement in lung CT was identified by LHQW in this meta-analysis (10 trials, n = 1134; RR = 1.23; 95 % CI: 1.14-1.34; I 2 = 49%, P <0.00001; Fig. 2a ). (a) Lung CT Clinical cure rate was defined as the following 4 discharge criterion in guideline for the diagnosis and treatment of COVID-19 infected pneumonia: a) body temperature returned to normal for more than 3 days, b) respiratory symptoms improved significantly, c) pulmonary imaging showed obvious absorption of inflammation, and d) two consecutive times of novel coronavirus nucleic acid test negative in respiratory tract (the sampling interval shall be at least 1 day) [7] . Nine trials evaluated the effects of LHQW on clinical cure rate [16, 17, 20, [25] [26] [27] [28] 30, 31] . There were 637 patients in experimental group and 516 in control group. LHQW exhibited a significant improvement on clinical cure rate (9 trials, n = 1153; RR = 1.24; 95 % CI: 1.08-1.42; I 2 = 76%, P =0.003; Fig. 2b ). (b) Clinical cure rate In this study effects of LHQW on ranging from mild to critical cases were evaluated in 10 trials [16] [17] [18] [19] [20] 24, 26, [29] [30] [31] . There were 693 patients in experimental group and 566 in control group. A significant improvement on ranging from mild to critical cases was observed by CHM (10 trials, n = 1259; RR = 0.48; 95 % CI: 0.35 to 0.65; I 2 = 0%, P < 0.00001; Fig. 2c ). (c) Range from mild to server or critical condition The effect of LHQW on death was reported in 4 trials [20, 21, 30, 31] . The symptom of cough was reported in all the trials, and only 9 were enrolled in this review [16] [17] [18] [19] 21, [23] [24] [25] 29 ]. Among them, 6 studies reported number of cough reduction cases [17] [18] [19] 21, 24, 29] , 4 studies reported disappearing time of cough [16, 17, 23, 29] , and 2 studies reported disappearing time of cough [20, 25] . In the field of number of cough reduction cases, there were 182 patients in experimental group and 167 in control group. A significant improvement on number of cough reduction cases was observed by LHQW in this study (6 trials, n = 349; RR = 1.53; 95 % CI: 1.25-1.87; I 2 = 33%, P < 0.0001; Fig. 3a ). The symptom of fever was reported in 13 trials [16] [17] [18] [19] [20] [21] [23] [24] [25] 27, [29] [30] [31] . Among them, 6 studies reported number of fever reduction cases [17] [18] [19] 21, 24, 29] , 9 reported fever reduction time [16] [17] [18] [19] 21, 23, 27, 30, 31] , and 2 reported disappearing time of fever [20, 25] . In the field of number of fever reduction cases, there were 174 patients in experimental group and 149 in control group. Meta analysis showed no significant difference on number of fever reduction cases between LHQW and CWM (6 trials, n = 323; RR = 1.25; 95 % CI: 0.96-1.64; I 2 = 0 %, P = 0.10; Fig. 4a ). Six trials evaluating length of hospital stay were included for further analysis in this study [21, 23, 26, 27, 30, 31] . There were 246 patients in experimental group and 152 in control group. Meta-analysis showed a significant reduction on length of hospital stay by LHQW (6 trials, n = 398; WMD: -0.80; 95 % CI: -1.37 to -0.23; I 2 = 49%, P = 0.006; Fig. 6a ). (a) Length of hospital stay The effect of LHQW on time for nucleic acid conversion was reported in 6 trials [16, 23, 24, 27, 30, 31] . There were 337 patients in experimental group and 296 in control group. Compared with CWM, a significant improvement on time for nucleic acid conversion was identified by LHQW (6 trials, n = 633; RR = -1.98; 95 % CI: -3.11--0.85; I 2 = 88%, P = 0.0006; Fig. 6b ). (b) Time for Nucleic Acid Conversion Clinical symptoms including fever, dry cough, expectoration, fatigue, sore throat, itchy throat, chest tightness, asthma, shortness of breath, poor appetite, diarrhea, nausea, vomiting, abdominal distention, and abdominal pain were reported in all the included studies [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . As fever, dry cough, and fatigue were main clinical symptoms of COVID-19, individual symptom score, disappearing time, number of improved cases, and total score of clinical symptom were summarized. Total score of clinical symptom was evaluated in 5 studies [20, 21, 25, 30, 31] . There were 290 patients in experimental group and 241 in control group. Meta analysis revealed a significant improvement on total score of clinical symptom (5 trials, n = 531; WMD: -2.67; 95 % CI: -3.54 to -1.79; I 2 = 65%, P < 0.00001; Fig. 6c ). (c) Total score of clinical symptoms The effect of LHQW on sore throat was evaluated in 5 studies [18] [19] [20] 25, 29] . Among them, 3 studies reported number of sore throat reduction cases [18, 19, 29] , and 2 reported individual symptom score [20, 25] . 98 %, P < 0.006; Fig. 7b ). (b) Symptom score of sore throat The effect of LHQW on chest tightness was evaluated in 6 studies [17] [18] [19] [20] 24, 25] . Among them, 4 studies reported number of chest tightness reduction cases [17] [18] [19] 24] , ad 2 reported individual symptom score [20, 25] . Three trials evaluating anhelation reduction cases were included for further analysis [17] [18] [19] . There were 39 patients in experimental group and 38 in control group. Compared to CWM, a significant improvement on number of anhelation reduction cases was observed by LHQW (3 trials, n = 77; RR = 3.43; 95 % CI: 1.68-7.02; I 2 = 0%, P = 0.0007; Fig. 8a ). (a) anhelation reduction cases In this study five trials evaluating expectoration reduction cases were included for further analysis [17] [18] [19] 21, 29] . There were 104 patients in experimental group and 79 in control group. No significant difference on number of expectoration reduction cases between LHQW and CWM was identified in this meta analysis (5 trials, n = 183; RR = 1.53; 95 % CI: 0.85-2.75; I 2 = 62%, P = 0.16; Fig. 8b ). (b) Expectoration reduction cases Three trials evaluating muscle pain reduction cases were included for further analysis [17] [18] [19] . There were 24 patients in experimental group and 25 in control group. A significant improvement on number of muscle pain reduction cases by LHQW was identified in this meta analysis (3 trials, n = 49; RR = 2.09; 95 % CI: 1.15-3.80; I 2 = 2%, P = 0.02; Fig. 8c ). (c) Muscle pain reduction cases Four trials evaluating sickness reduction cases were included for further analysis [17] [18] [19] 24] . There were 37 patients in experimental group and 20 in control group. No significant difference on number of sickness reduction cases between LHQW and CWM was identified in this meta analysis (4 trials, n = 57; RR = 1.12; 95 % CI: 0.79-1.61; I 2 = 37%, P =0.52; Fig. 8d ). (d) Sickness reduction cases Two trials evaluating headache reduction cases were included for further analysis [18, 19] . There were 10 patients in experimental group and 7 in control group. No significant difference on number of headache reduction cases between LHQW and CWM was identified (2 trials, n = 17; RR = 1.36; 95 % CI: 0.67-2.80; I 2 = 0%, P = 0.40; Fig. 9a ). (a) Headache reduction cases Four trials evaluating anorexia reduction cases were included for further analysis [17] [18] [19] 24] . There were 88 patients in experimental group and 85 in control group. No significant difference on number of anorexia reduction cases between LHQW and CWM was identified (4 trials, n = 173; RR = 1.72; 95 % CI: 0.83-3.58; I 2 = 86%, P = 0.14; Fig. 9b ). (b) Anorexia reduction cases Three trials evaluating diachoea reduction cases were included for further analysis [18, 19, 24] . There were 21 patients in experimental group and 11 in control group. No significant difference on number of diachoea reduction cases between LHQW and CWM was identified (3 trials, n = 32; RR = 1.09; 95 % CI: 0.69-1.72; I 2 = 0%, P = 0.72; Fig. 9c ). (c) Diachoea reduction cases In this review, 7 trials reported adverse effects (7/16, 43 .75 %) [16, 19, 20, 21, 23, 28, 30] . Among them, no adverse effect was identified in both LHQW and CWM groups [20, 21, 28, 30] . Adverse effects in the rest 2 trials included gastrointestinal reactions (abdominal distention, diarrhea, abdominal pain, nausea, vomiting, belching, acid reflux, poor appetite), headache, dizziness, drowsiness, abnormal liver function, renal dysfunction, and drug allergy [16, 19] . All of the reported adverse effects were released spontaneously in both LHQW and CWM groups. Meta-analysis identified that no significant difference between CHM and CWM was identified (7 trials, n = 946; RR = 0.73; 95 % CI: 0.38-1.40; I 2 = 60%, P = 0.34; Fig. 11a ). (e) Adverse effects Publication bias was detected by the funnel plot of indicators studied. The asymmetry showed a mild publication bias, and the results were reliable in the study (Fig. 11 ). [16] . Forsythia suspensa and honeysuckle are king drugs to clear away heat, detoxify, eliminate plague and eliminate evil, which could block the binding of SARS-CoV-2 with the angiotensin converting enzyme [36] ; Roasted ephedra and fried bitter almonds are minister drugs to relieve lung heat, relieve asthma and cough; Rhubarb has the effect of clearing heat and cooling blood, purging fire and detoxifying, which could effectively resist the binding of spinous process protein and angiotensin converting enzyme [40] , and inhibit the excessive release of inflammatory mediators, and improve lung injury [41] ; Banlangen, Mianma Guanzhong, patchouli, Houttuynia cordata, menthol, clear heat and detoxification, dispel wind and promoting pharynx, which has been shown to improve diarrhea and host defense of gastrointestinal tract [37] ; Gypsum can clear away heat and cool blood, reduce fire and eliminate annoyance; Rhodiola can invigorate Qi and blood circulation, relieve cough and asthma, which could ameliorate lung injury via the suppression of oxidative stress and apoptosis [38] and abrogation of pulmonary inflammation [39] . Licorice blend, applied in all drugs, has the effects of warming the lung, strengthening the spleen and removing dampness [23] . These observations provide evidence for the antiviral effect of LHQW. Limitations in this review should also be mentioned. Firstly, Although the 16 trials collected in the study are far more than similar studies, the sample is still relatively small, and almost all comes from China, which has a certain impact on the methodological quality of literatures, and leads to language bias. Secondly, some studies adopted open distribution and lacked blind methods for participants, which led to high-risk bias. Thirdly, there is statistical heterogeneity in the research results of some indicators, such as clinical cure rate, disappearing time of cough. Therefore, random effect model was adopted. Due to the small sample size,subgroup analysis, multilevel meta-analysis, perceptual analysis and other methods in line with clinical characteristics were hardly carried out. Fourthly, the significant effect of LHQW in the treatment of COVID-19 was analyzed merely from the aspect of pharmaceutical components, which needs further research and confirmation. To sum up, The evaluation results of this systematic review and Meta analysis suggested that, in the treatment of COVID-19, LHQW Capsule (Granule) could not only significantly improve the fever symptoms, shorten the fever time, but also reduce the cough and fatigue symptoms, improve the clinical efficiency, improve the lung CT, significantly reduce the number of patients with mild to severe diseases, and have certain anti-inflammatory effect. And there is no server adverse events which support the safety of LHQW Capsule (Granule) for the treatment of COVID-19. As a classic formula of TCM, LHQW Capsule (Granule) could be used as potential candidates for COVID-19 in this battle. L.F. was involved in all parts of the study: design, acquisition of data, analysis, interpretation, drafting of paper, and final approval. L.P.Q., Y.Z. and H.F.S. participated in study select, data extraction, and assessment of the methodological quality. H.F.S. helped to revise the manuscript. L.F. and H.F.S. contributed to the interpretation of the data and made critical comments on the manuscript to be published. The authors declare no competing financial interests. Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence Clinical effects of integrated traditional Chinese and western medicine on COVID-19: a systematic review Herbal medicine for the treatment of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis of randomized controlled trials An Analyze of The Traditional Chinese Medicine Prevention and Treatment Interventions For COVID-19 Mechanism of covid-19 inflammatory storm and intervention effect of traditional Chinese Medicine Clinical Effectiveness and Case Analysis in 54 NCP Patients Treated with Lanhuaqingwen Granules Clinical efficacy of traditional Chinese medicine Lianhua Qingwen Granules in 42 suspected cases of children with Corona Virus Disease Efficacy of Early Combination Therapy With Lianhuaqingwen and Arbidol in Moderate and Severe COVID-19 Patients: A Retrospective Cohort Study Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) Oseltamivir compared with the Chinese traditional therapy Maxingshigan-Yinqiaosan in the treatment of H1N1 influenza: a randomized trial Current situation and perspectives of clinical study in integrative medicine in China Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Efficacy and safety of Chinese herbal medicine for patients with postmenopausal hypertension: a systematic review and meta-analysis Efficacy and safety of herbal medicine (Lianhuaqingwen) for treating COVID-19: A systematic review and meta-analysis Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb Analysis of curative effect of 51 patients with novel coronavirus pneumonia treated with Chinese medicine Lianhua Qingwen: a multicentre retrospective study Retrospective Clinical Analysis on Treatment of Coronavirus Disease 2019 with Traditional Chinese Medicine Lianhua Qingwen A clinical observation of 63 cases of novel coronavirus pneumonia suspected cases treated with Lianhua Qingwen granule Clinical efficacy of Lianhua Qingwen granule combined with abidol in treating coronavirus disease Clinical study on treatment of early New Coronavirus pneumonia based on Lianhua Qingwen capsule combined with traditional Chinese medicine and Western Medicine Positive effects of Lianhuaqingwen granules in COVID-19 patients: A retrospective study of 248 cases Clinical study of Lianhua Qingwen Capsule in the treatment of corona virus disease Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: A randomized controlled trial Clinical Study on Treatment of COVID-19 in Convalescent Period Treated with Lianhua Qingwen Capsule Combined with Interferon α-2b Efficacy Study of Arbidol, Qingfei Paidu Decoction, Lianhua Qingwen Capsule, and Jinye Baidu Granules in the Treatment of Mild/Moderate COVID-19 in a Fangcang Shelter Hospital Retrospective analysis of treatment of common New Coronavirus pneumonia with Jin Ye Baidu granule and Lianhua Qingwen capsule Arbidol combined with the Chinese medicine Lianhuaqingwen capsule versus arbidol alone in the treatment of COVID-19 Study on clinical efficacy of Lianhua Qingke Granule in treatment of mild and ordinary COVID-19 Clinical study on 34 novel coronavirus pneumoniae treated with integrated traditional Chinese and western medicine Clinical observation on 49 cases of non-critical coronavirus disease 2019 in Shanghai treated by integrative traditional Chinese and western medicine Pondering over COVID-19 Prevented and Treated by Traditional Chinese Medicine Clinical efficacy of Lianhua Qingwen integrated with Western medicine on COVID-19 by Meta-analysis Literature analysis of Lianhua Qingwen combined with western medicine in treating COVID-19 Clinical efficacy of Lianhua Qingwen integrated with Western medicine on COVID-19 by Meta-analysis Rapid establishment of traditional Chinese medicine prevention and treatment of 2019-nCoV based on clinical experience and molecular docking Study on the regulation mechanism of patchouli active components on intestinal smooth muscle nerve conduction in IBS-D rats Salidroside intervention improves lung injury in mice with chronic intermittent hypoxia Protective effffect of salidroside on lung injury in rats with acute respiratory distress syndrome Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction Effffect of rhubarb extract on TNF-α and IL-8 expression in rabbit lung after cardiopulmonary resuscitation This study was funded by the project of National Natural Science Foundation of China